Adrenocorticotropic Hormone in Membranous Nephropathy

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy. Acthar is a hormone that stimulates steroid production from small glands above the kidneys. It has direct protective effects on the kidney and is currently approved by the FDA to treat kidney disorders associated with proteins in the urine, but the mechanisms of action are not entirely understood and will be studied in the present trial.

Clinical Trial Description

Patients with membranous nephropathy and nephrotic syndrome will be treated with ACTH for 6 months. Proteinuria remission at 12 months will be the primary endpoint. Different biomarkers including anti-PLA2R autoantibodies, circulating regulatory T cells, and autoreactive memory B cells will be serially measured to identify predictors of response to therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03025828
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	Phase 4
Start date	March 19, 2018
Completion date	December 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04095156` - Autoreactive B Cells in Membranous Nephropathy
Not yet recruiting	`NCT06341205` - Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)	Phase 3
Active, not recruiting	`NCT04893096` - MOR202 for Refractory MN	Phase 2
Completed	`NCT00405340` - Rituximab in the Treatment of Idiopathic Membranous Nephropathy	Phase 0
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Active, not recruiting	`NCT04652570` - Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy	Phase 1/Phase 2
Not yet recruiting	`NCT06242327` - An Outcome Analysis of Primary Membranous Nephropathy
Recruiting	`NCT03929887` - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting	`NCT03949855` - Belimumab With Rituximab for Primary Membranous Nephropathy	Phase 2
Completed	`NCT00983034` - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy	N/A
Recruiting	`NCT05732402` - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases	Phase 1/Phase 2
Enrolling by invitation	`NCT04571658` - NEPTUNE Match Study
Active, not recruiting	`NCT05894512` - Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Not yet recruiting	`NCT05941845` - Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy	Phase 2
Completed	`NCT00518219` - To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)	Phase 4
Completed	`NCT02199145` - Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy	N/A
Not yet recruiting	`NCT04326218` - Immunopathological Analysis in a French National Cohort of Membranous Nephropathy	N/A
Active, not recruiting	`NCT03453619` - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies	Phase 2
Completed	`NCT01955187` - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy	Phase 3
Completed	`NCT04733040` - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)	Phase 2